<SEC-DOCUMENT>0000950170-25-094383.txt : 20250707
<SEC-HEADER>0000950170-25-094383.hdr.sgml : 20250707
<ACCEPTANCE-DATETIME>20250707190825
ACCESSION NUMBER:		0000950170-25-094383
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250702
FILED AS OF DATE:		20250707
DATE AS OF CHANGE:		20250707

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Weis Holger
		CENTRAL INDEX KEY:			0001846984
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		251109275

	MAIL ADDRESS:	
		STREET 1:		C/O ZIOPHARM ONCOLOGY, INC.
		STREET 2:		ONE FIRST AVENUE, PARRIS BLDG 34
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02129

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 233
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 233
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-07-02</periodOfReport>

    <issuer>
        <issuerCik>0001107421</issuerCik>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>TCRT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001846984</rptOwnerCik>
            <rptOwnerName>Weis Holger</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ALAUNOS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2617 BISSONNET ST, SUITE 233</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>770005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.02</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-07-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>130000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-07-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>130000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>130000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">25% of this grant will vest and become exercisable immediately upon grant and the remaining balance shall vest in substantially equal quarterly installments over a three year period commencing on the Start Date with the first vesting date being October 2, 2025, subject to holder's continuous employment through each vesting date. This option grant shall be subject to the terms and conditions of the Company's 2020 Equity Incentive Plan and a Stock Option Agreement.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Melinda Lackey, Attorney-in-Fact</signatureName>
        <signatureDate>2025-07-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
